$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
How long does it take to achieve the desired effect of sparsentan?
2026-02-01 22:25:32
Check Details
Will there be resistance to Ixazomib (Enleri) and analysis of countermeasures
2026-02-01 22:25:32
Check Details
Usage, dosage and individualized adjustment plan of rubitin/rubicatin (Zanbiga)
2026-02-01 22:25:32
Check Details
Pimitespib medical insurance reimbursement process and related policy instructions
2026-02-01 22:25:32
Check Details
Can afatinib (Giteri) be taken separately and what precautions should be taken?
2026-02-01 22:25:32
Check Details
Explanation of medication monitoring indicators and safety assessment methods for DaliRasheng (Keweike)
2026-02-01 22:25:32
Check Details
Contraindications and precautions for taking Lynparza (Lipdrox) together with other drugs
2026-02-01 22:25:32
Check Details
Detailed explanation of venetoclax/venetoclax (venetoclax) onset time and treatment course evaluation recommendations
2026-02-01 22:25:32
Check Details
How long does it take for Asnib/Asiminib to take effect and evaluation of the course of treatment?
2026-02-01 22:25:32
Check Details
Regular purchasing channels for Ritlecitinib and precautions for patients when purchasing the drug
2026-02-01 22:25:32
Check Details
Treatment methods and coping strategies when side effects of sparsentan occur
2026-02-01 22:25:32
Check Details
Clinical trial data and efficacy analysis of ixazomib (Enleri)
2026-02-01 22:25:32
Check Details
1
2
...
2203
2204
2205
2206
2207
2208
2209
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma